Log in

CVE:RXBiosyent Stock Price, Forecast & News

+0.04 (+0.96 %)
(As of 05/28/2020 06:00 AM ET)
Today's Range
Now: C$4.21
50-Day Range
MA: C$4.06
52-Week Range
Now: C$4.21
Volume6,763 shs
Average Volume16,921 shs
Market CapitalizationC$54.15 million
P/E Ratio13.58
Dividend YieldN/A
BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used in agriculture. BioSyent Inc. distributes its products to pharmacies and hospitals. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$21.42 million
Cash FlowC$1.67 per share
Book ValueC$1.91 per share



Market CapC$54.15 million
Next Earnings Date5/28/2020 (Confirmed)
OptionableNot Optionable

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.

Biosyent (CVE:RX) Frequently Asked Questions

How has Biosyent's stock been impacted by COVID-19 (Coronavirus)?

Biosyent's stock was trading at C$4.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RX stock has decreased by 3.2% and is now trading at C$4.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biosyent?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biosyent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biosyent.

When is Biosyent's next earnings date?

Biosyent is scheduled to release its next quarterly earnings announcement on Thursday, May 28th 2020. View our earnings forecast for Biosyent.

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) announced its earnings results on Wednesday, March, 18th. The company reported $0.08 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.09 by $0.01. The business earned $5.57 million during the quarter, compared to the consensus estimate of $6.10 million. View Biosyent's earnings history.

What price target have analysts set for RX?

2 equities research analysts have issued 1 year price objectives for Biosyent's stock. Their forecasts range from C$6.00 to C$7.50. On average, they anticipate Biosyent's share price to reach C$6.75 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View analysts' price targets for Biosyent.

Has Biosyent been receiving favorable news coverage?

News articles about RX stock have been trending somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biosyent earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBiosyent.

Who are some of Biosyent's key competitors?

What other stocks do shareholders of Biosyent own?

Who are Biosyent's key executives?

Biosyent's management team includes the following people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Kevin Wilson, VP of Community Health Bus.
  • Mr. Sharan Raghubir MBA, Director of the Hospital Bus. Unit - Biosyent Pharma Inc
  • Mr. Alfred D'Souza, Advisor
  • Mr. Robert March, VP of Fin. & CFO

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of Biosyent?

Shares of RX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Biosyent's stock price today?

One share of RX stock can currently be purchased for approximately C$4.21.

How big of a company is Biosyent?

Biosyent has a market capitalization of C$54.15 million and generates C$21.42 million in revenue each year.

What is Biosyent's official website?

The official website for Biosyent is www.biosyent.com.

How can I contact Biosyent?

Biosyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.